Bcr-Abl and Imatinib (STI571 or Gleevec)

From Proteopedia

Jump to: navigation, search

c-Abl tyrosine kinase: SH3 domain is shown in red while SH2 domain is shown in purple. The catalytic domain is represented in blue. It is also possible to observe myristoyl group in the N-terminal domain of c-Abl tyrosine kinase (PDB code 1opk)

Drag the structure with the mouse to rotate

3D structures

Tyrosine kinase

Authors

Almudena Chaves Pérez; Julio César Corral Serrano; Cristina Murga Montesinos.

Some morphs and scenes were reproduced from the pages of David Canner. We acknowledge the help of Elisa Lucas.

References

  1. Yuan ZM, Huang Y, Ishiko T, Kharbanda S, Weichselbaum R, Kufe D. Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci U S A. 1997 Feb 18;94(4):1437-40. PMID:9037071
  2. Wang JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene. 2000 Nov 20;19(49):5643-50. PMID:11114745 doi:10.1038/sj.onc.1203878
  3. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002 Aug 1;62(15):4236-43. PMID:12154025
  4. O'Hare T, Walters DK, Stoffregen EP, Sherbenou DW, Heinrich MC, Deininger MW, Druker BJ. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6987-93. PMID:16203792 doi:10.1158/1078-0432.CCR-05-0622
  5. Ramakrishnan C, Dani VS, Ramasarma T. A conformational analysis of Walker motif A [GXXXXGKT (S)] in nucleotide-binding and other proteins. Protein Eng. 2002 Oct;15(10):783-98. PMID:12468712
  6. Johnson DA, Akamine P, Radzio-Andzelm E, Madhusudan M, Taylor SS. Dynamics of cAMP-dependent protein kinase. Chem Rev. 2001 Aug;101(8):2243-70. PMID:11749372
  7. Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, Dinitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7. Epub 2009 Jan 21. PMID:19164557
  8. Leukemia research 34 (10): 1255–1268. doi:10.1016/j.leukres.2010.04.016. PMID 2053738
  9. Zhao X, Ghaffari S, Lodish H, Malashkevich VN, Kim PS. Structure of the Bcr-Abl oncoprotein oligomerization domain. Nat Struct Biol. 2002 Feb;9(2):117-20. PMID:11780146 doi:10.1038/nsb747
  10. http://atlasgeneticsoncology.org/Genes/ABL.html
  11. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol. 2006 Jul;2(7):358-64. PMID:16783341 doi:10.1038/nchembio799
  12. Scheinfeld N. A comprehensive review of imatinib mesylate (Gleevec) for dermatological diseases. J Drugs Dermatol. 2006 Feb;5(2):117-22. PMID:16485879
  13. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005 Feb;7(2):129-41. PMID:15710326 doi:S1535-6108(05)00028-0
  14. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, Tanaka C, Manley P, Rae P, Mietlowski W, Bochinski K, Hochhaus A, Griffin JD, Hoelzer D, Albitar M, Dugan M, Cortes J, Alland L, Ottmann OG. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 Jun 15;354(24):2542-51. PMID:16775235 doi:10.1056/NEJMoa055104
  15. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 Jul 16;305(5682):399-401. PMID:15256671 doi:10.1126/science.1099480
  16. Cortes JE, Jones D, O'Brien S, Jabbour E, Ravandi F, Koller C, Borthakur G, Walker B, Zhao W, Shan J, Kantarjian H. Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia. J Clin Oncol. 2010 Jan 20;28(3):398-404. doi: 10.1200/JCO.2009.25.4920. Epub 2009, Dec 14. PMID:20008620 doi:10.1200/JCO.2009.25.4920
  17. Khoury HJ, Cortes JE, Kantarjian HM, Gambacorti-Passerini C, Baccarani M, Kim DW, Zaritskey A, Countouriotis A, Besson N, Leip E, Kelly V, Brummendorf TH. Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood. 2012 Apr 12;119(15):3403-12. doi: 10.1182/blood-2011-11-390120. Epub 2012 , Feb 27. PMID:22371878 doi:10.1182/blood-2011-11-390120
  18. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm318203.htm
  19. Manley PW, Cowan-Jacob SW, Mestan J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. Biochim Biophys Acta. 2005 Dec 30;1754(1-2):3-13. Epub 2005 Sep 8. PMID:16172030 doi:10.1016/j.bbapap.2005.07.040
  20. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009 Nov 6;16(5):401-12. PMID:19878872 doi:10.1016/j.ccr.2009.09.028
  21. Frame D. New strategies in controlling drug resistance in chronic myeloid leukemia. Am J Health Syst Pharm. 2007 Dec 15;64(24 Suppl 15):S16-21. PMID:18056927 doi:10.2146/ajhp070483
  22. An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010 Oct;34(10):1255-68. PMID:20537386 doi:10.1016/j.leukres.2010.04.016
  23. Olivieri A, Manzione L. Dasatinib: a new step in molecular target therapy. Ann Oncol. 2007 Jun;18 Suppl 6:vi42-6. PMID:17591830 doi:10.1093/annonc/mdm223
  24. Boschelli, F.; Arndt, K.; Gambacorti-Passerini, C. (2010). "Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia". European journal of cancer (Oxford, England : 1990) 46 (10): 1781–1789.doi:10.1016/j.ejca.2010.02.032. PMID 20399641. edit)
  25. Cortes J, Kim DW, Raffoux E, Martinelli G, Ritchie E, Roy L, Coutre S, Corm S, Hamerschlak N, Tang JL, Hochhaus A, Khoury HJ, Brummendorf TH, Michallet M, Rege-Cambrin G, Gambacorti-Passerini C, Radich JP, Ernst T, Zhu C, Van Tornout JM, Talpaz M. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008 Dec;22(12):2176-83. doi: 10.1038/leu.2008.221. Epub 2008 Aug 28. PMID:18754032 doi:10.1038/leu.2008.221
  26. An X, Tiwari AK, Sun Y, Ding PR, Ashby CR Jr, Chen ZS. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res. 2010 Oct;34(10):1255-68. PMID:20537386 doi:10.1016/j.leukres.2010.04.016

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Alexander Berchansky, Joel L. Sussman, Cristina Murga

Personal tools